ATE526945T1 - Verfahren zur erhöhung von fibronectin - Google Patents

Verfahren zur erhöhung von fibronectin

Info

Publication number
ATE526945T1
ATE526945T1 AT03789843T AT03789843T ATE526945T1 AT E526945 T1 ATE526945 T1 AT E526945T1 AT 03789843 T AT03789843 T AT 03789843T AT 03789843 T AT03789843 T AT 03789843T AT E526945 T1 ATE526945 T1 AT E526945T1
Authority
AT
Austria
Prior art keywords
peptides
compositions
development
fibronectin
increase
Prior art date
Application number
AT03789843T
Other languages
English (en)
Inventor
Sohail Malik
Stephen Quirk
Original Assignee
Kimberly Clark Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kimberly Clark Co filed Critical Kimberly Clark Co
Application granted granted Critical
Publication of ATE526945T1 publication Critical patent/ATE526945T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
AT03789843T 2002-12-30 2003-11-18 Verfahren zur erhöhung von fibronectin ATE526945T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/335,207 US7148194B2 (en) 2002-12-30 2002-12-30 Method to increase fibronectin
PCT/US2003/037053 WO2004060908A2 (en) 2002-12-30 2003-11-18 Method to increase fibronectin

Publications (1)

Publication Number Publication Date
ATE526945T1 true ATE526945T1 (de) 2011-10-15

Family

ID=32655292

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03789843T ATE526945T1 (de) 2002-12-30 2003-11-18 Verfahren zur erhöhung von fibronectin

Country Status (9)

Country Link
US (1) US7148194B2 (de)
EP (1) EP1578780B1 (de)
KR (1) KR20050092026A (de)
CN (1) CN1756839A (de)
AT (1) ATE526945T1 (de)
AU (1) AU2003294360B2 (de)
CA (1) CA2511557A1 (de)
MX (1) MXPA05007227A (de)
WO (1) WO2004060908A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189700B2 (en) * 2003-06-20 2007-03-13 Kimberly-Clark Worldwide, Inc. Anti-chrondrosarcoma compounds
US20060068364A1 (en) * 2004-09-29 2006-03-30 Struck James T Methods and devices for the prevention and treatment of gingival recession
CA2586035A1 (en) * 2004-11-01 2006-05-11 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles in use for aesthetic or cosmetic medicine, and methods of manufacture and use
US7645583B2 (en) * 2005-12-14 2010-01-12 Kimberly-Clark Worldwide, Inc. Identification of compounds for inhibiting complexation of C-reactive protein with fibronectin
TWI415628B (zh) * 2006-02-28 2013-11-21 Avon Prod Inc 包含具有非天然胺基酸之胜肽之組合物及其使用方法
US7879798B1 (en) 2007-08-24 2011-02-01 Regenicel, Inc. Composition for indolent wound healing and methods of use therefor
CN104911168B (zh) * 2015-06-30 2018-03-30 中国人民解放军第三军医大学第一附属医院 I型胶原蛋白高亲和力多肽及其应用
SG11201808528VA (en) 2016-03-30 2018-10-30 Convatec Technologies Inc Modified wound dressings

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2507379A1 (fr) 1981-06-05 1982-12-10 Europ Composants Electron Bloc de condensateurs en serie et multiplicateur de tension utilisant un tel bloc de condensateurs
US5270447A (en) 1988-05-20 1993-12-14 The United States Of America As Represented By The Department Of Health & Human Services Metalloproteinase peptides: role in diagnosis and therapy
US5280106A (en) 1988-05-20 1994-01-18 Liotta Lance A Matrix metalloproteinase peptides: role in diagnosis and therapy
US5698671A (en) 1989-03-21 1997-12-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Metalloproteinase peptides
CA2074507A1 (en) 1990-01-26 1991-07-27 William G. Stetler-Stevenson Method for quantitatively measuring collagenase
EP1262493A1 (de) 1992-10-29 2002-12-04 Bayer Corporation Diagnostischer Test spezifisch für die latente Matrix Metalloproteinase no. 9
JP3098640B2 (ja) 1992-12-24 2000-10-16 富士薬品工業株式会社 ヒト７２−ｋＤａゼラチナーゼ／ＩＶ型コラゲナーゼの免疫学的定量法
JP2673929B2 (ja) 1993-04-12 1997-11-05 富士薬品工業株式会社 ヒト間質型コラゲナーゼと阻害剤との複合体の免疫学的定量法および臨床診断への応用
US6150152A (en) 1993-05-28 2000-11-21 Washington University Human macrophage metalloelastase
AU7128494A (en) 1993-07-09 1995-02-06 Celltech Limited Gelatinase antagonists used for treating cancer
AU675870B2 (en) 1993-08-18 1997-02-20 Msd K.K. Endothelin antagonistic heteroaromatic ring-fused cyclopentene derivatives
JPH07303482A (ja) 1993-11-30 1995-11-21 Fuji Yakuhin Kogyo Kk 新規なメタロプロテアーゼおよびそれをコードするｄｎａ
JPH07159402A (ja) 1993-12-09 1995-06-23 Kyodo Nyugyo Kk Ｉｖ型コラゲナ−ゼ測定法
JPH07330795A (ja) 1994-06-07 1995-12-19 Toagosei Co Ltd ペプチドおよびモノクローナル抗体
US5811252A (en) 1994-07-07 1998-09-22 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Modified proenzymes as substrates for proteolytic enzymes
DE19524720A1 (de) 1995-07-12 1997-01-16 Hoechst Ag Zellspezifische Gentherapie mit Hilfe eines neuen Promotors für den "Tissue Inhibitor of Metalloproteinasn-3"
JPH08134098A (ja) 1994-11-11 1996-05-28 Morinaga & Co Ltd ヒトｔｉｍｐ−１の高感度測定法
JPH08136548A (ja) 1994-11-11 1996-05-31 Morinaga & Co Ltd 泌尿器癌の診断法
ES2281898T3 (es) 1994-12-13 2007-10-01 Human Genome Sciences, Inc. Inhibidor tisular humano de metaloproteinasa-4.
JP2949467B2 (ja) 1995-02-16 1999-09-13 富士薬品工業株式会社 免疫学的測定法によるヒトプロマトリックスメタロプロテアーゼ７の定量
US5770691A (en) 1995-06-05 1998-06-23 Regents Of The University Of Minnesota Discriminatory substrates for MMP hydrolysis
US6191255B1 (en) 1995-07-14 2001-02-20 Fuji Yakuhin Kogyo Kabushiki Kaisha Protein and monoclonal antibody specific thereto
JPH0987299A (ja) 1995-07-14 1997-03-31 Fuji Yakuhin Kogyo Kk Ｍｍｐ−２活性化因子に特異的なモノクローナル抗体
JPH0984589A (ja) 1995-07-14 1997-03-31 Fuji Yakuhin Kogyo Kk 新規なタンパク質
IT1277904B1 (it) 1995-08-07 1997-11-12 Polifarma Spa Metodo per determinare l'attivita' terapeutica di composti inibitori di metalloproteinasi, nuovi composti inibitori, e loro impiego
EP1019528B1 (de) 1996-01-04 2003-10-29 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Methode zur bestimmung von proteolytischen enzyme unter benutzung von fluoreszenzgelöschten substraten
JPH09206099A (ja) 1996-01-31 1997-08-12 Sekisui Chem Co Ltd 細胞機能測定方法
GB9615976D0 (en) 1996-07-30 1996-09-11 Center For Clinical & Basic Re The use of proteinase inhibitors for the prevention or reduction of bone resorption
US6022948A (en) 1996-09-17 2000-02-08 Washington University Method of cell surface activation and inhibition
US20020099004A1 (en) 1996-12-06 2002-07-25 Lund Leif Roge Inhibition of invasive remodelling
US6046031A (en) 1997-01-21 2000-04-04 Human Genome Sciences, Inc. Metalloproteinases
JPH10210982A (ja) 1997-01-31 1998-08-11 Fuji Yakuhin Kogyo Kk 新規なタンパク質
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
AU6443498A (en) 1997-03-07 1998-09-22 Tropix, Inc. Protease inhibtor assay
WO1998040475A1 (en) 1997-03-11 1998-09-17 Abbott Laboratories Human matrix metalloprotease gene, proteins encoded therefrom and methods of using same
AUPO573697A0 (en) 1997-03-20 1997-04-10 Prince Henry's Institute Of Medical Research Diagnosis of endometrial cancer
JPH10287700A (ja) 1997-04-10 1998-10-27 Fuji Yakuhin Kogyo Kk 活性型マトリライシン（ｍｍｐ−７）に対する抗体及びそれを用いた免疫学的測定法
JPH10313896A (ja) 1997-05-15 1998-12-02 Yamanouchi Pharmaceut Co Ltd マトリックスメタロプロテアーゼに対する発色団又は蛍光団を有する新規な活性測定用合成基質
US6043087A (en) 1997-07-25 2000-03-28 The New York Blood Center Monospecific antibody reactive with matrix metalloproteinase cleavage products of fibrin(ogen)
EP0917165B1 (de) 1997-11-14 2007-04-11 Murata Manufacturing Co., Ltd. Vielschichtkondensator
JP2002533055A (ja) 1997-12-19 2002-10-08 ワイス 軟骨の変性疾患のためのトランスジェニック動物モデル
AU3980499A (en) 1998-05-11 1999-11-29 Endowment for Research in Human Biology, Inc., The Use of neomycin for treating angiogenesis-related diseases
WO1999065519A1 (en) 1998-06-16 1999-12-23 The General Hospital Corporation Matrix metalloproteinase proenzyme activator
US6191225B1 (en) 1998-08-31 2001-02-20 Ppg Industries Ohio, Inc. Thermosetting compositions containing carboxylic acid functional polymers and epoxy functional polymers prepared by atom transfer radical polymerization
WO2000020860A1 (en) 1998-10-08 2000-04-13 Calbiochem Novabiochem Corporation Diagnostic assay for matrix metalloproteinase 9 and use thereof
US6753310B1 (en) 1998-10-16 2004-06-22 Otsuka Pharmaceutical Co., Ltd. Neovascular-specific peptides
USH1973H1 (en) * 1998-10-22 2001-07-03 Novartis Ag Human neutrophil collagenase splice variant
KR20010102556A (ko) 1999-03-11 2001-11-15 추후제출 암 및 과증식성 장애의 치료 조성물 및 치료방법
JP2000270874A (ja) 1999-03-25 2000-10-03 Fuji Chemical Industries Ltd 新規な膜結合型メタロプロテアーゼ
US6274717B1 (en) 1999-04-20 2001-08-14 Smithkline Beecham Corporation Splicing variant of human membrane-type matrix metalloproteinease-5 (MT-MMP5-L)
WO2000074634A2 (en) 1999-06-03 2000-12-14 Au Jessie L S Methods and compositions for modulating cell proliferation and cell death
JP2001072589A (ja) 1999-07-06 2001-03-21 Toagosei Co Ltd 制癌剤
US6403637B1 (en) 1999-08-09 2002-06-11 Univ Saint Louis Methods of modulating matrix metalloproteinase activity and uses thereof
AU6940700A (en) 1999-08-26 2001-03-19 Amy P. N Skubitz Peptides capable of modulating the function of cd66 (ceacam) family members
GB9927576D0 (en) 1999-11-23 2000-01-19 Univ Birmingham Novel assay
US20020063763A1 (en) 2000-11-29 2002-05-30 Mantell David Allen Apparatus and method for removing air bubbles from an ink jet printhead
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
WO2001062206A2 (en) 2000-02-22 2001-08-30 Mount Sinai School Of Medicine Of New York University N-cadherin modulated migration, invasion, and metastasis
GB0004531D0 (en) 2000-02-25 2000-04-19 Richards Andrew J M The treatment of respiratory diseases
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US7094754B2 (en) 2001-08-16 2006-08-22 Kimberly-Clark Worldwide, Inc. Anti-aging and wound healing compounds
US7071164B2 (en) 2001-08-16 2006-07-04 Kimberly-Clark Worldwide, Inc. Anti-cancer and wound healing compounds
US6906036B2 (en) * 2001-08-16 2005-06-14 Kimberly-Clark Worldwide, Inc. Anti-aging and wound healing compounds
US7189700B2 (en) 2003-06-20 2007-03-13 Kimberly-Clark Worldwide, Inc. Anti-chrondrosarcoma compounds

Also Published As

Publication number Publication date
MXPA05007227A (es) 2005-09-12
EP1578780B1 (de) 2011-10-05
US20040127421A1 (en) 2004-07-01
CN1756839A (zh) 2006-04-05
AU2003294360B2 (en) 2010-02-25
AU2003294360A1 (en) 2004-07-29
WO2004060908A3 (en) 2005-08-04
KR20050092026A (ko) 2005-09-16
WO2004060908A2 (en) 2004-07-22
US7148194B2 (en) 2006-12-12
CA2511557A1 (en) 2004-07-22
EP1578780A2 (de) 2005-09-28
EP1578780A4 (de) 2008-05-14

Similar Documents

Publication Publication Date Title
MXPA04001034A (es) Compuestos para sanar heridas y en contra de envejecimiento.
DE60142590D1 (de) Verwendung von Botulinum Toxin zur Behandlung von post-operative Schmerzen
DK2015723T3 (da) Integreret sårforbindingssystem
ATE371457T1 (de) Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
SI2298338T1 (sl) Laktoferinski sestavki in postopki za zdravljenjekožnih ran
ATE395928T1 (de) Expressionsvektoren und zellinien zur expression von vaskulärem wachstumsfaktor d, sowie verfahren zur behandlung von melanomen
DE10085007T1 (de) Antiinfektionszusammensetzungen zur Behandlung von erkranktem Gewebe, wie Lippenherpes
ATE551976T1 (de) Verfahren zur herstellung eines festen verbands zur behandlung von verletztem gewebe
DE60023816D1 (de) Verwendung von Lycopin in Zusammensetzungen zur Behandlung von Hautalterungs-Erscheinungen
WO2005079822A3 (en) Pharmaceutical composition comprising a fibrin matrix and dermal fibroblasts for the treatment of wounds
ATE421877T1 (de) Verwendung von totarol zur behandlung von pruritus
DE60313434D1 (de) Verfahren und zusammensetzungen zur behandlung von hyperproliferativen zuständen
EP1430933A3 (de) Kosmetische und pharmazeutische Zusammensetzungen enthaltend Steroidsulfatase-Inhibitoren und deren Verwendung zur Verminderung von Haarausfall
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
ATE526945T1 (de) Verfahren zur erhöhung von fibronectin
ATE332705T1 (de) Verwendung von in der mittlere oder späte follikuläre phase verabreichte lh zur behandlung von anovulatorischen frauen
DE59707519D1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
ES2113222T3 (es) Utilizacion de derivados de acido benzoico para estimular el proceso de renovacion epidermica y tratar la piel.
TWI348912B (en) Method and composition for treating skin wounds with epidermal growth factor
ATE255426T1 (de) Dermales hüllgewebe in der wundheilung
DE60214207D1 (de) Nagellack enthaltend tazaroten und verwendung dessen zur behandlung und/oder zur prävention von psoriasis
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
EP1330271A4 (de) Verwendung von transkriptionsfaktoren zur behandlung von entzündungen und anderen erkrankungen
ATE275580T1 (de) Verfahren zur induktion der herstellung von wachstumsfaktoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties